Catalyst Wire Dossier Catalyst Wire Dossier

Claudin18.2-targeted Chimeric Antigen Receptor T cells

· Peking University
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Claudin18.2-targeted Chimeric Antigen Receptor T cells, covering 2024-04-30 to 2024-04-30. Get the full timeline:

Most recent: Clinical Trial Update: Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. [Phase 1]

See pricing